SLC7A11 and neoplasm: Current applications of SLC7A11 in the treatment of tumours can be broadly classified into two categories: direct targeting of SLC7A11 transporter activity, which inhibits tumour progression by inducing intracellular ROS accumulation and ferroptosis, and targeting metabolic vulnerabilities exposed by SLC7A11-overexpressing cancer cells, such as glucose or glutamine dependency [21].